Business Area

  • Cancer
  • Carcinoma of Unknown Primary
  • Extended Profile
  • Rescue Drug
  • Incrementally Modified Drug
  • Orphan Drug
  • Infectious Disease
  • Cancer
  • Using our unique cancer-specific data set containing 23+ different
    types of cancers with over 70,000 relevant patients’ prognosis data,
    we can help pharmaceutical companies developing anti-cancer
    drugs to select the most appropriate cancer types for a given anti-cancer agent.

    Phamaceutical companies can better able to identify the specific
    cancer market, design clinical trials to improve the success rate of
    clinical approval, and manage pipeline strategy.

  • Carcinoma of Unknown Primary
  • Carcinoma of Unknown Primary (CUP) is a diverse group of
    cancers that is defined by the presence of metastatic disease
    with no identified primary tumor at initial presentation.
    CUP is reported to comprise approximately 2% to 5% of all
    cancer cases and conventional immunohistochemical staining
    methods can only find 70% of the primary site of CUP.
    ONCOfind AI can identify the primary site of CUP with 99%
    accuracy with proprietary transcriptomic dataset of over
    70,000 cancer patients of multiple races and 40 main types of
    cancers with 79 subtype with various phenotype information.

  • Extended Profile
  • Pharmaceutical companies spend billions of dollars in the early
    stages of drug discovery to get to a single lead compound opti-
    mization. Using our drug and disease data set, we can screen
    additional indications for drug compounds that are in the
    preclinical stage in the Phase I clinical trials. Subsequently,
    the screened new or additional indications can begin Phase
    II or Phase I / IIa clinical trials directly.
    Pharmaceutical companies can increase the value of the drug
    compound under development by adding additional pipeline
    without spending billions of dollars in many years.

  • Rescue Drug
  • New drug compounds typically have approximately 86%
    failure rates during clinical trials. We screen to find a new
    indication for drug compounds that have failed in Phase II
    or III clinical trials, thus, failed to show efficacy for the
    originally targeted indication. Since the compound has
    been tested for toxicity by passing Phase I clinical trial,
    we can conduct preclinical efficacy test only and directly
    begin Phase II clinical trial.
    Pharmaceutical companies can save, on average, 95% of
    the cost and 7 years in time from the compound discovery
    stage to Phase I clinical trials.

  • Incrementally Modified Drug
  • We take marketed drugs to select the most suitable combination
    of two or more drugs by changing the formulation or chemical
    structure to improve the delivery speed, safety, and efficacy of
    the drugs.
    Compared to the conventional new drug development process,
    it costs less and can be developed faster while reducing the
    clinical trial risks.

  • Orphan Drug
  • There are over 7,000 rare diseases worldwide and less than
    only 6% of the disease have approved treatment.
    Using our proprietary transcriptomic patients data, drug
    data, and disease data with 19+ rare disease cohorts, we
    can screen and repurpose existing marketed drugs with
    known pharmacokinetics and pharmacodynamics to find
    the solution for rare disease.

  • Infectious Disease
  • Pandemic situation like COVID-19 requires rapid development
    of vaccines or new drugs, especially when the disease is prone
    to mutation. Up until now, there is no established treatment
    for COVID-19, so other types of antiviral drugs for AIDS or Flu
    has been administered. However, we can still see cytokine
    storm in some patients even when the viral load decreases.
    Given the merits of AI technology's speed and accuracy, we
    can effectively screen to develop the optimal combination
    therapy that can improve the symptoms while suppressing
    cytokine bursts.
    We are currently collaborating with Korea’s Infectious Disease
    Department, University Hospital, and Korea Institute of
    Bioscience and Biotechnology in an effort to find the
    suitable treatment.